CD47 and neuroblastoma: Indeed, these encouraging findings are supported by other preclinical studies which demonstrated CD47 upregulation following anti-GD2 treatment functions as an adaptive immune checkpoint which limits effective ADCC in neuroblastoma models.69 Thus, dual targeting of GD2 and CD47 represents a promising strategy for clinical translation in neuroblastoma.